Today on Drug Discovery & Development
Layoff tracker: Mapping the 8,600-plus biotech and pharma layoffs in early 2024
[Updated on April 24, 2024] While a number of biotech startups continue to attract healthy funding amounts, the biotech sector continues to see a significant number of layoffs in 2024 with major cuts hitting firms like Amylyx Pharmaceuticals, Novartis, Genentech and Sanofi. Amylyx Pharmaceuticals is downsizing its workforce by about 70% following the decision to…FDA approves pair of therapies for rare pediatric cancers: Novartis’ Lutathera and Day One’s Ojemda
The FDA has signed off on two novel therapies targeting rare pediatric cancers. Novartis’ Lutathera targets aggressive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in children 12 and up, while Day One Biopharma’s Ojemda (tovorafenib) tackles treatment-resistant BRAF-mutated relapsed or refractory pediatric low-grade glioma (pLGG) with a BRAF fusion or rearrangement, or BRAF V600 mutation These approvals offer…Drug Discovery and Development See More >
New pharma and biotech manufacturing facilities and expansions announced worldwide for 2024
[Updated April 23, 2024] In the face of rising R&D costs and growing pricing pressures from payers, the pharma and biotech sectors continue to transform to adapt to an evolving landscape. While workforce reductions persist in 2024 for some companies, major players like AbbVie, AGC Biologics, Amgen, Novartis and Thermo Fisher Scientific are demonstrating confidence…
Sponsored Content See More >
Genomics/Proteomics See More >
Study combines biomimetic AI, digital twins and multiomics to unveil potential genetic drivers of endometriosis
Endometriosis, a condition where endometrial tissue grows outside the uterus, has a strong genetic underpinning. A new study published in the Journal of Molecular Diagnostics sheds light on this connection. Researchers from a team including Genzeva, LumaGene, RYLTI Biopharma, Brigham & Women’s Hospital of Harvard University and QIAGEN Digital Insights used a unique approach in…
Unleashing a new frontier: The power of germline clinico-genomic data to drive therapeutic development
NVIDIA expands BioNeMo platform with new foundation models and microservices for AI-powered Drug Discovery
Navigating the cancer progression pathway with liquid biopsy
Microsoft and 1910 Genetics: AI-powered partnership targets billion-dollar savings and growth in drug discovery
Infectious Disease See More >
Public vs. private: Who’s leading the charge in H5N1 preparedness?
The recent emergence of H5N1 avian influenza in humans and animals has intensified global efforts to prepare for a potential pandemic. Public health agencies and international organizations are collaborating with pharmaceutical companies and academic institutions to develop vaccines, treatments, and strategies to mitigate the impact of an outbreak. The CDC, for instance, has released interim…
Best-selling pharmaceuticals of 2023 reveal a shift in pharma landscape
Lumen Bioscience cracks the code on spirulina as a biologics factory for c. diff, metabolic disease and more
Vaccine mega-trials: Rare behemoths in the vaccine trial landscape
Biden names 31 tech hubs: Here are 10 relevant to pharma and biotech
Oncology See More >
FDA approves pair of therapies for rare pediatric cancers: Novartis’ Lutathera and Day One’s Ojemda
The FDA has signed off on two novel therapies targeting rare pediatric cancers. Novartis’ Lutathera targets aggressive gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in children 12 and up, while Day One Biopharma’s Ojemda (tovorafenib) tackles treatment-resistant BRAF-mutated relapsed or refractory pediatric low-grade glioma (pLGG) with a BRAF fusion or rearrangement, or BRAF V600 mutation These approvals offer…